DB05114ExperimentalSmall molecule
EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
- Mechanism
- Curator reviewed
EHC18 is an oral compound thought to modulate immune responses to HCV by inducing tolerance, or non-responsiveness to viral antigens, thus potentially reducing inflammation.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C) and hepatocellular carcinoma.Curator reviewed
- Code names
- EHC18
Which companies are running trials of EHC18, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account